original article Wien Klin Wochenschr https://doi.org/10.1007/s00508-019-01556-1 Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma Data of real-world utilization in Austria Andreas Seeber · Lukas Weiss · Franz Romeder · Joanna Szkandera · Thomas Kuehr · Susanne Kostner · Petra Pichler · Thomas Jaeger · Florian Kocher · Richard Greil · Thomas Brodowicz Received: 27 May 2019 / Accepted: 16 September 2019 © Springer-Verlag GmbH Austria, part of Springer Nature 2019 Summary Background Olaratumab is a humanized monoclonal antiplatelet-derived growth factor receptor alpha antibody that has been approved in combination with doxorubicin for the treatment of patients with metastatic soft tissue sarcoma (STS). The purpose of this retrospective study was to assess the clinical efficacy in STS patients treated with olaratumab in a real-world setting in Austria. Methods Retrospectively collected longitudinal data from patients treated between November 2016 and September 2018at 9 Austrian centers were obtained from the respective medical charts. All patients who received at least one dose of olaratumab were eligible. Parameters of most interest were response rates, pro- gression-free survival (PFS) and overall survival (OS). A. Seeber, MD PhD () · F. Kocher Department of Internal Medicine V: Hematology and Oncology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria andreas.seeber@tirol-kliniken.at L. Weiss · R. Greil IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria F. Romeder Internal Medicine I: Department of Medical Oncology, Haematology and Gastroenterology, Hospital Barmherzige Schwestern Linz, Linz, Austria J. Szkandera Division of Clinical Oncology, Medical University of Graz, Graz, Austria Results Altogether 55 patients were included in the analysis. The median age was 58 years. In total, 65.5% (n = 36), 21.8% (n = 12) and 12.7% (n = 7) received olaratumab as first, second or ≥third line treatment, respectively. Olaratumab was administered either in combination with doxorubicin (81.8%, n = 45) or lipo- somal doxorubicin (16.4%, n = 9); one patient received olaratumab as upfront monotherapy. The median PFS and OS were 2.6 and 11.4 months, respectively. The objective response rate was 11.4% and the disease control rate was 40.9%. Conclusion In this real-world analysis the outcome was less pronounced compared to the results of both the phase Ib/II approval trial and the confirmatory phase III trial. The latter failed to show an improve- ment in OS and PFS for the doxorubicin/olaratumab T. Kuehr Department of Internal Medicine IV, Hospital Wels-Grieskirchen, Wels, Austria S. Kostner Department of Internal Medicine, Hospital of Schwaz, Schwaz, Austria P. Pichler Department of Internal Medicine I, Hospital of St. Poelten, St. Poelten, Austria T. Jaeger Internal Medicine II: Medical Oncology, Hematology, Gastroenterology and Rheumatology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria T. Brodowicz Department of Internal Medicine I/Clinical Division of Medical Oncology, Medical University Vienna—General Hospital, Vienna, Austria K Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma